Neuroendocrine tumour isotope treatment with 177Lu-peptide or PRRT (1 procedure)
PRRT or peptide receptor therapy is a treatment method, in which a tumour cell specific peptide shall be marked with radioactive lutetium and the drug shall be administered to the patient intravenously as a slow drip infusion.
This treatment method shall be used to treat metastasized neuroendocrine tumours. For the course of the treatment (up to 2 days), the patient shall be isolated into a special radiation-shielded treatment room where they can use a shower and toilet, Wi-Fi, TV, radio, fridge, kettle, etc. The procedure also includes whole body scanning and three-dimensional SPET/CT recording to detect the number and locations of tumour lesions.
You can come to the treatment only with a specialist’s referral.